| 2.08 1.06 (103.92%) | 04-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.75 |
1-year : | 3.76 |
| Resists | First : | 2.36 |
Second : | 3.22 |
| Pivot price | 2.23  |
|||
| Supports | First : | 0.97 | Second : | 0.8 |
| MAs | MA(5) : | 1.58 |
MA(20) : | 2.37 |
| MA(100) : | 1.45 |
MA(250) : | 1.1 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 37.4 |
D(3) : | 26.5 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 5.69 | Low : | 0.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SXTC ] has closed above bottom band by 42.8%. Bollinger Bands are 40.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.22 - 3.25 | 3.25 - 3.26 |
| Low: | 1.16 - 1.17 | 1.17 - 1.18 |
| Close: | 2.06 - 2.08 | 2.08 - 2.1 |
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.
Tue, 15 Apr 2025
SXTC stock hits 52-week low at $2.31 amid sharp annual decline - Investing.com
Thu, 03 Apr 2025
SXTC stock plunges to 52-week low at $2.4 amid steep annual decline - Investing.com
Mon, 17 Mar 2025
China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency - GlobeNewswire
Mon, 17 Mar 2025
China SXT Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Price Requirement - Nasdaq
Fri, 21 Feb 2025
China SXT Pharmaceuticals announces 1-for-8 share consolidation - Investing.com
Fri, 21 Feb 2025
Will SXTC's Share Consolidation Save Its Nasdaq Listing? Key Dates Revealed - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 14 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 33 (K) |
| Shares Short P.Month | 5 (K) |
| EPS | 124.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 30.79 |
| Profit Margin | 318.6 % |
| Operating Margin | -77 % |
| Return on Assets (ttm) | 18.1 % |
| Return on Equity (ttm) | 57.6 % |
| Qtrly Rev. Growth | -11.7 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | 0.13 |
| EBITDA (p.s.) | 0.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | 0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.06 |
| Price to Sales | 15.72 |
| Price to Cash Flow | -10.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|